TARGETED INHIBITION OF LEUKEMIA INHIBITORY FACTORY (LIF)/LIFR AXIS FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER

The University Of Texas Health Science Center At San Antonio

Investigators